AVITA Medical Inc(RCEL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.44 | Insider Own | 1.93% | Shs Outstand | 30.9M | Perf Week | 0.9% |
| Market Cap | 0.39B | Forward P/E | - | EPS next Y | 59.31% | Insider Trans | 11.44% | Shs Float | 24.4M | Perf Month | 30.31% |
| Enterprise Value | 0.43B | PEG | - | EPS next Q | -0.24 | Inst Own | 20.05% | Short Float | 11.64% | Perf Quarter | 238.74% |
| Income | -0.04B | P/S | 5.14 | EPS this Y | 45.66% | Inst Trans | -2.6% | Short Ratio | 5.95 | Perf Half Y | 252.48% |
| Sales | 0.08B | P/B | - | EPS next 5Y | - | ROA | -81.36% | Short Interest | 2.84M | Perf YTD | 353.62% |
| Book/sh | -0.9 | P/C | 34.9 | EPS past 3/5Y | -17.81% 3.38% | ROE | -1746.27% | 52W High | -7.4% ($16.90) | Perf Year | 326.43% |
| Cash/sh | 0.45 | P/FCF | - | Sales past 3/5Y | 27.66% 38.09% | ROIC | - | 52W Low | 386.02% ($3.22) | Perf 3Y | 67.02% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 26.76% | Gross Margin | 81.56% | Volatility(W/M) | 5.97% 6.3% | Perf 5Y | -4.98% |
| Dividend TTM | - | EV/Sales | 5.63 | Sales Y/Y TTM | 1% | Oper. Margin | -46.57% | ATR (14) | 0.86 | Perf 10Y | 55.72% |
| Dividend Ex-Date | - | Quick Ratio | 0.34 | EPS Q/Q | 33.76% | Profit Margin | -56.96% | RSI (14) | 66.15 | Recom | 1.67 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.41 | Sales Q/Q | 17.83% | SMA20 | 9.67% ($14.27) | Beta | 2.09 | Target Price | $12.99 |
| Payout | - | Debt/Eq | - | Earnings | 2026/11/5 | SMA50 | 28.2% ($12.21) | Rel Volume | 1.25 | Prev Close | $16.71 |
| Employees | 226 | LT Debt/Eq | - | EPS/Sales Surpr. | 14.62% 6.12% | SMA200 | 138.85% ($6.55) | Avg Volume(3M) | 0.48M | Price | $15.65 |
| IPO | 2012/3/29 | Option/Short | Yes/Yes | Trades | 6827 | Volume | 597,088 | Change | -6.34% |
🩹 Avita Medical (RCEL) is a U.S. medical device company focused on regenerative medicine-based wound and skin treatments. It commercializes autologous cell regeneration technology that uses a patient's own skin cells to treat burns, soft-tissue defects, and skin pigmentation disorders, with hospitals and burn treatment centers serving as its primary customers.
Over the past 1 year, on the higher side
7% below its 1-year high.
Traded about as much as usual. That is 125% of its average volume.
Next earnings report: November 5
5 days to go.
RCEL has weak earnings and a weak balance sheet
Of every $100 in sales, $46.57 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +45.7% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $514. Peers typically go for $326.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -5.0%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 20.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #64 of 142 in the industry
Based on market cap of $389M.
SI#63 Shoulder Innovations Inc $398M PER - RCEL#64 AVITA Medical Inc $389M PER - 
OFIX#65 Orthofix Medical Inc $369M PER - 
VMD#66 Viemed Healthcare Inc $368M PER 26.4 
CV#67 CapsoVision Inc $363M PER - 
FAQ
What kind of company is RCEL?
RCEL belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of RCEL?
The market cap of RCEL is approximately $389M, ranking 3,353 within its sector.
What is the 52-week high and low for RCEL?
RCEL has recorded a 52-week high of $16.90 and a low of $3.22.
